SNDX Q4 2017 Earnings — Syndax Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SNDXSyndax Pharmaceuticals, Inc.

$2B

Q4 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M+291.1% YoY

Gross Profit

$1M100.0% margin

Operating Income

-$19M-1633.6% margin

Net Income

-$19M-1601.3% margin

EPS (Diluted)

$-0.80

QoQ Revenue Growth

+291.1%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$137M

Total Liabilities

$33M

Stockholders' Equity

$104M

Cash & Equivalents

$35M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$305,000	+291.1%
Gross Profit	$1M	$305,000	+291.1%
Operating Income	-$19M	-$11M	-74.9%
Net Income	-$19M	-$11M	-76.6%